Brief: TCR² Therapeutics Reports Q3 Loss Per Share Of $0.58
12/11/2019 12:25
Nov 12 (Reuters) - TCR2 Therapeutics Inc TCRR.O :
* TCR² THERAPEUTICS REPORTS THIRD QUARTER 2019 FINANCIAL
RESULTS
AND PROVIDES CORPORATE UPDATE
* TCR2 THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.58
Source text for Eikon: ID:nGNX2X9k5H
Further company coverage: TCRR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TCR2 Therapeutics
See all newsBrief: TCR2 Therapeutics Entered Into An Assignment Of Lease Agreement With Astrazeneca
TCR2 Therapeutics falls on bigger-than-expected Q1 loss
Brief: Tcr² Therapeutics Reports Q1 2023 Financial Results And Provides Corporate Update
TCR2 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
TCR2 Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview